Samsung Biologics, a manufacturer of bio-healthcare products, has joined forces with PharmAbcine to develop and manufacture PMC-402 pipeline, an advanced therapeutic antibody candidate to treat oncology and neovascular disorders.

Under the partnership agreement, Samsung has agreed to provide the full scope of its CDO services including cell line development, process development, cGMP clinical manufacturing to IND filing support.

PharmAbcine CEO Jin-San Yoo said: “The anti-cancer effect of PMC-402, both as a monotherapy and a combination therapy with immuno-cancer drugs, was confirmed through initial research. From this year, we will test the safety of PMC-402 and initiate phase I clinical trial by 2021 through collaboration with Samsung Biologics.”

PharmAbcine seeks to expand the indication for PMC-402 to include eye diseases

PharmAbcine is engaged in developing fully human therapeutic antibodies to treat cancer and neovascular disease, and its lead molecule Olinvacimab is currently in phase 2 clinical trials for a combination therapy to treat cancer with Merck’s Keytruda.

According to the biopharmaceutical firm, PMC-402 would enhance the delivery of immune cells and cancer therapeutics to treat tumour cells via active normalisation of leaky blood vessels.

The company intends to expand the indication of the candidate based on vessel normalization properties, to include eye diseases like wet age-related macular degeneration (wAMD) and diabetic retinopathy (DR).

Established in 2011, Samsung Biologics is an advanced CMO, CDO, and CRO offering contract development, manufacturing, and laboratory testing services to support the development and manufacturing of biologics products.

Samsung Biologics CEO Tae-Han Kim said: “Offering full range of services in development, manufacturing, and laboratory testing from our state-of-the-art facilities, Samsung Biologics works intimately with our clients to reach IND and market Faster & Better.

“Through partnership with Samsung Biologics, biotech companies can not only benefit from fast timeline and high-quality products, but also concentrate on discovery activity, a core aspect of their business.”